Potassium canrenoate

Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.[3][4]

Potassium canrenoate
Clinical data
Other namesSC-14266
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Intravenous
ATC code
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal and fecal
Identifiers
  • potassium 3-[(8R,9S,10R,13S,14S,17R)-
    17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,
    11,12,14,15,16-octahydro-1H-cyclopenta[a]
    phenanthren-17-yl]propanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.016.868
Chemical and physical data
FormulaC22H29KO4
Molar mass396.568 g·mol−1
3D model (JSmol)
  • [K+].[O-]C(=O)CC[C@]3(O)CC[C@H]2[C@@H]4/C=C\C1=C\C(=O)CC[C@@]1([C@H]4CC[C@@]23C)C
  • InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1 Y
  • Key:JTZQCHFUGHIPDF-RYVBEKKQSA-M Y
 NY (what is this?)  (verify)

Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)[4][5] as opposed to oral administration.[6]

In the UK it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.

See also

References
  1. Hans Selye (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.
  2. R.A. Hill; H.L.J. Makin; D.N. Kirk; G.M. Murphy (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
  3. Alfred Burger; Manfred E. Wolff (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.
  4. Carl Waldmann; Neil Soni; Andrew Rhodes (27 November 2008). Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.
  5. H. Jaap Bonjer (21 June 2017). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.
  6. Kolkhof P, Bärfacker L (2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". J. Endocrinol. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.